Losigamone

From WikiMD's WELLNESSPEDIA

Losigamone is an antiepileptic drug that was developed for the treatment of epilepsy, a neurological disorder characterized by recurrent seizures. It is a member of the class of drugs known as gamma-aminobutyric acid (GABA) enhancers, which work by increasing the activity of GABA, a neurotransmitter in the brain that inhibits the firing of neurons and thus helps to prevent seizures.

History[edit]

Losigamone was first synthesized in the late 1980s by the German pharmaceutical company Schwarz Pharma. It was initially developed as a potential treatment for epilepsy, but its development was discontinued in the late 1990s due to concerns about its safety and efficacy.

Mechanism of Action[edit]

Losigamone works by enhancing the activity of GABA, a neurotransmitter that inhibits the firing of neurons in the brain. It does this by binding to a specific site on the GABA receptor, which increases the receptor's sensitivity to GABA. This increased sensitivity results in an increased inhibitory effect on neuronal firing, which can help to prevent seizures.

Clinical Trials[edit]

Several clinical trials were conducted in the 1990s to evaluate the safety and efficacy of losigamone in patients with epilepsy. These trials showed that losigamone was effective in reducing the frequency of seizures in some patients. However, the drug was also associated with a number of side effects, including dizziness, fatigue, and weight gain. These side effects, combined with concerns about the drug's long-term safety, led to the decision to discontinue its development.

Current Status[edit]

As of 2021, losigamone is not approved for use in any country. However, research into its potential uses continues. Some studies have suggested that it may have potential as a treatment for other neurological disorders, such as Parkinson's disease and Huntington's disease, but further research is needed to confirm these findings.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Losigamone&oldid=6307316"